Qiagen.com

QIAGEN.COM NEWSROOM (7 press releases)

Advanced Filtering & Sorting Options:

Archive by Year: All 2025 2024 2023 2022 2021 2017 2016 2015 2014 2013 2012

QIAGEN Ergebnisse einer neuen Evaluierung im Bereich der Frauengesundheit die hohe Genauigkeit seiner Bioinformatik-Lösungen untermauern

PRESS RELEASE -- 20, October 2017

Ergebnisse der Evaluierung der QCI-Plattform zur Interpretation klinisch relevanter Genvarianten werden auf der ASHG 2017 von Counsyl vorgestellt Orlando, Florida (USA), Germantown, Maryland (USA), und Hilden (Deutschland), 20-Oct-2017 — /EuropaWire/ — QIAGEN (NASDAQ: QGEN; Frankfurter Börse: QIA) gab heute bekannt, … Read the full press release →

France’s Ministry of Health and Social Affairs approves reimbursement for QIAGEN’s QuantiFERON-TB® Gold Plus latent tuberculosis test

PRESS RELEASE -- 23, June 2017

Gold-standard test for latent tuberculosis infection will be covered by national health insurance Hilden, Germany, and Paris, France, 23-Jun-2017 — /EuropaWire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that France’s Ministry of Health and Social Affairs … Read the full press release →

DiaSorin, QIAGEN to develop new tests for DiaSorin’s LIAISON family of analyzers

PRESS RELEASE -- 23, June 2017

Saluggia, Italy; Hilden, Germany, and Germantown, Maryland, USA, 23-Jun-2017 — /EuropaWire/ — DiaSorin (FTSE Italy Mid Cap: DIA) and QIAGEN (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) announced today a new collaboration to develop new tests for DiaSorin’s LIAISON family of … Read the full press release →

U.S. FDA premarket approval for QIAGEN’s automated artus® CMV QS-RGQ MDx kit for use on its QIAsymphony platform

PRESS RELEASE -- 7, June 2017

High-throughput application of artus CMV QS-RGQ MDx Kit on QIAsymphony streamlines critical and frequently performed viral infection test for transplant patients Germantown, Maryland, and Hilden, Germany, 07-Jun-2017 — /EuropaWire/ — QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has … Read the full press release →

QIAGEN receives worldwide license from The Johns Hopkins University for biomarkers for immune-oncology therapies in cancer treatment

PRESS RELEASE -- 7, June 2017

Option to add new biomarkers for microsatellite instability (MSI) and mismatch repair (MMR) to QIAGEN’ s NGS panels Hilden, Germany, and Germantown, Maryland, 07-Jun-2017 — /EuropaWire/ — QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received a worldwide … Read the full press release →

Bristol-Myers Squibb and QIAGEN to explore NGS technology to develop GEPs for I-O therapies in cancer treatment

PRESS RELEASE -- 6, June 2017

NEW YORK and HILDEN, Germany, 06-Jun-2017 — /EuropaWire/ — Bristol-Myers Squibb Company (NYSE: BMY) and QIAGEN(NASDAQ: QGEN; Frankfurt Prime Standard: QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as  … Read the full press release →

QIAGEN N.V. forms joint venture with Maccura Biotechnology Co., Ltd., a leading in vitro diagnostics (IVD) company in China

PRESS RELEASE -- 8, May 2017

Partnership with a leading Chinese IVD company with goal to accelerate penetration of the world’s first complete Sample to Insight NGS solution in rapidly growing Chinese market Hilden, Germany, and Chengdu, China, 08-May-2017 — /EuropaWire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt … Read the full press release →